Scientists present new outlook on latest trends in peptide drug discovery and development

NewsGuard 100/100 Score

Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development. Due to their beneficial properties, these biomolecules play already an important role in the treatment of diseases such as diabetes, cancer, hormone disorders, HIV infection, and multiple sclerosis.

In the recent issue of "Nature Reviews Drug Discovery", a team of Austrian and Australian scientists led by medicinal chemist Markus Muttenthaler of the University of Vienna present an outlook on the latest trends in peptide drug discovery and development.

"Insulin is a prime example for a successful peptide drug that has been essential for the health of millions of diabetic patients in the past 100 years," says Markus Muttenthaler, who leads research groups at the Institute of Biological Chemistry of the Faculty of Chemistry at University in Vienna as well as at the Institute for Molecular Bioscience, at the University of Queensland in Brisbane.

Worldwide, peptide therapeutics account for 5% of the global pharmaceutical market, with global sales exceeding US$ 50 billion. More than 150 peptides are in clinical development and another 400-600 peptides undergoing preclinical studies.

Peptide drugs have a distinct space in the pharmaceutical landscape. They are smaller than small molecule drugs, which hold the largest share of therapeutics on the market, and larger than genetically produced biologics such as antibodies.

Compared to small molecules, peptides are often more potent and selective, and thus have fewer side effects; compared to antibodies, their production is more economic and they have certain advantages in cancer research, e.g. they can penetrate (tumor) tissue more easily. However, 90% of peptide drugs need to be injected, since the digestive system breaks them down rapidly when taken orally.

Vast peptide libraries

According to the corresponding authors, Assoc. Prof. Markus Muttenthaler and his Australian colleague, Prof. Paul F. Alewood, the increased interest in peptide drugs demands "efficient strategies for the discovery of therapeutic leads". A key trend in peptide drug discovery is the establishment and directed evolution of vast peptide libraries based on latest display technologies, a concept that has been recognized with the Nobel Prize in Chemistry in 2018.

The systematic exploration of animal venoms is another key trend that drives peptide drug discovery, and "allows us to take advantage of the vast natural and over millions of years evolutionary-selected peptide libraries for therapeutic lead discovery", says Muttenthaler, who is very active in this space.

New insights

In a recent study, Muttenthaler's team chemically conjugated a spider-venom peptide with a scorpion-venom peptide. Both substances use different mechanisms to block an ion channel that plays an important role in pain signaling. "Linking the two different binding mechanisms resulted in irreversible blockage of the ion channel, and the concept might be useful for prolonged pain relief," says Muttenthaler.

In a second study, his team, together with Christophe Duplais' group in French Guyana, analyzed the venom of the Brazilian ant species, Pseudomyrmex penetrator, and synthesized and characterized the most active component. The potent paralytic effect of the isolated venom peptide against plant pests could serve as a promising lead for environmentally friendly and less hazardous biopesticides.

Identifying the right space within the drug landscape

Peptides are signaling molecules of life that control many physiological functions:

When investigating natural products and complex antibiotics such as vancomycin, it can often take years to establish a chemical synthesis; newly discovered peptide compounds, however, can be synthesized in days, which greatly accelerates the research and development of new peptide therapeutics. It is however crucial to identify the right pharmacological space where your peptide drug can outperform small molecule drugs or biologics."

Markus Muttenthaler, Medicinal Chemist, University of Vienna

Journal reference:

Muttenthaler, M., et al. (2021) Trends in peptide drug discovery. Nature Reviews Drug Discovery.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Monash-led study unveils potential long-term treatment for lupus